BackgroundThe risk of biochemical recurrence (BCR) in prostate cancer (PCa) is typically assessed using D'Amico score. However, iron and fat content in PCa are closely related to tumor cell proliferation and the risk of BCR may be estimated using multiparametric MRI (mpMRI).PurposeTo noninvasively estimate fat and iron content in PCa and to evaluate their utility in enhancing D'Amico scores for predicting BCR in PCa patients.Study TypeProspective.SubjectsForty‐eight male patients in the BCR group (age 71.31 ± 5.74 years) and 27 male patients in the non‐BCR group (age 70.3 ± 6.04 years).Field Strength/Sequence3.0 T, Turbo‐spin echo T2‐weighted imaging, diffusion‐weighted imaging (DWI), dynamic contrast‐enhanced (DCE) imaging, Gradient echo Q‐Dixon sequence.AssessmentThe mean fat fraction (FF) and T2* values of lesions were extracted from the FF map and the T2* map. Additionally, prostate volume, mean apparent diffusion coefficient (ADC) value, periprostatic fat thickness (PPFT), subcutaneous fat thickness (SFT), blood lipid content, pre‐ and post‐operative prostate‐specific antigen (PSA) values were collected.Statistical TestsStepwise‐COX regression analysis was employed to identify the significant predictors of BCR, which led to the construction of an improvement‐adjusted (IA) model. Then the IA model as well as the D'Amico score were evaluated using C‐index and time‐dependent AUC, decision‐curve analysis, and Kaplan–Meier curve. P < 0.05 was statistically significant.ResultsSignificant differences were observed in PSA, D'Amico score, ISUP grade, T2*, FF, and ADC values of the lesions in the BCR group compared with the non‐BCR group. Mean T2*, FF, and ADC values of the lesions were screened to construct the IA model incorporated into the D'Amico score (IA Model: C‐index = 0.749; AUC = 0.812; D'Amico score: C‐index = 0.672; AUC = 0.723).Data ConclusionThis study demonstrated that mpMRI can quantitatively estimate fat and iron within PCa lesions. By integrating ADC, FF, and T2* values into the D'Amico score, the preoperative‐risk assessment for BCR can be improved.Evidence Level2Technical EfficacyStage 2
